Form S-1
2021-09-30 to 2023-05-05 · 63 questions
· 9 letters from the SEC, 0 from the company
No closing letter
RevenueResults discussion (MD&A)Risk factorsLiquidity and cashControlsCritical estimatesGoodwill and impairmentInventory
Draft Registration Statement · Cover Page
SEC asked (1)
Please clarify that you will be a "controlled company" on the cover page but have elected not to take advantage of the controlled company exemption to the corporate governance rules for publicly listed companies.
TEM answered
No reply letter found.
Prospectus Summary, page 1
SEC asked (2)
Your disclosure on page 9 indicating that you have two algorithmic tests appears inconsistent with your disclosure elsewhere on page 30 indicating that you have three algorithmic tests. Please revise the disclosure to resolve this inconsistency or explain.
TEM answered
No reply letter found.
Prospectus Summary, page 1
SEC asked (3)
Please provide additional context regarding your revenue in 2020 and the six months ended June 30, 2021. Disclose the portion of your revenue generated from COVID-19 testing for each period. Also disclose that you expect your COVID-19 revenue to decrease due to the expiration of your agreement with CVS in July 2021 and as the prevalence of COVID-19 subsides and as other COVID-19 testing providers enter the market.
TEM answered
No reply letter found.
Our Three Product Lines, page 5
SEC asked (4)
Please disclose the percentage of revenue generated from each of the three product lines. We note that the substantial majority of your total revenue is generated from genomics and the revenue from Algo has not been significant.
TEM answered
No reply letter found.
Data, page 6
SEC asked (5)
Please revise your disclosures on pages 7-8 regarding the cohort graphics as follows: • Clarify the differences (if any) between sequencing revenue presented here and genomics revenue as presented on the face of your financial statements. • Describe the limitation of these analyses. For example, revise to explain the types of revenues and cost of revenues excluded from these analyses.Rest of the question
• Since you do not present any gross profit measures on the face of your GAAP income statement, please remove references to the phrase "gross profit" from these analyses. • Revise the note below the 2020 Cohort table on page 8 to quantify the cost of subsequent data revenue that is excluded from the cohort analysis for each period presented. • Make similar revisions as needed to the cohort analyses presented on pages 105-106 and 147-148.
TEM answered
No reply letter found.
Risk Factors · Risks Related to Our Business and Strategy, page 22
SEC asked (6)
Please discuss the material terms of your contract with the Illinois Department of Health, including any termination provisions.
TEM answered
No reply letter found.
Risk Factors · Risks Related to Our Business and Strategy, page 22
SEC asked (7)
You disclose on page 31 that mentions in peer-reviewed journal publications are a good indicator of success. We also note your disclosure on page 163 indicating that you have self-authored 29 of 41 total articles in which you have been mentioned. Please revise your risk factor to include possible conflicts of interest related to such self-publications.Rest of the question
We rely on a limited number of suppliers or, in some cases, sole suppliers..., page 41
TEM answered
No reply letter found.
Risk Factors · Risks Related to Our Business and Strategy, page 22
SEC asked (8)
You disclose that you rely on sole suppliers such as Illumina, Inc. for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that you use in your laboratory operations. Please disclose the material terms of your agreement with Illumina, including term and termination provisions. Tell us what consideration you have to filing this agreement as an exhibit.Rest of the question
See Item 601(b)(10) of Regulation S-K. We have identified a material weakness in our internal control over financial reporting, page 74
TEM answered
No reply letter found.
Risk Factors · Risks Related to Our Business and Strategy, page 22
SEC asked (9)
You state that you have taken steps to remediate the material weakness in your internal controls by hiring a Chief Accounting Officer and other key technical accounting and financial reporting roles to further develop and document your accounting policies and financial reporting procedures, including ongoing senior management review.Rest of the question
You also state that you will continue to work to remediate this material weakness by hiring additional qualified accounting and financial reporting personnel, training existing personnel, and improving your accounting processes. Please disclose how long you estimate it will take to complete your plans and any associated material costs that you have incurred or expect to incur.
TEM answered
No reply letter found.
We are highly dependent on the services of Eric Lefkofksy ..., page 77
SEC asked (10)
We note your disclosure that you are highly dependent on the services of Eric Lefkofsky, your Founder, Chief Executive Officer and Chairman of your board of directors. Please disclose the percentage of his time that he devotes to the business of the company given his other responsibilities as the co-founder and Executive Chairman of the board of Pathos AI, Inc.Rest of the question
and the managing partner and co-founder of Lightbank LLC.
TEM answered
No reply letter found.
Management's Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 112
SEC asked (11)
You state that the increases in Genomics revenue in 2020 and the six months ended June 30, 2021 were attributable primarily to the increases in the number of next generation sequencing clinical tests delivered. Please disclose the number of clinical test that were delivered for each period presented.
TEM answered
No reply letter found.
Comparison of the Six Months Ended June 30, 2020 and 2021, page 112
SEC asked (12)
For all periods presented, please revise to provide greater context to your discussion of changes in revenue between periods. For example, please revise to quantify the extent to which increases are attributable to increases in prices or volume of tests performed in the Genomics product category or the number of new subscription agreements in the data and other product category.Rest of the question
Please refer to Item 303(a)(3)(iii) of Regulation S-K. Cash Flows, page 117
TEM answered
No reply letter found.
Comparison of the Six Months Ended June 30, 2020 and 2021, page 112
SEC asked (13)
In order to provide investors with a better understanding of your business as a whole, please revise your discussion of cash flows for all periods presented so that the causes for changes in cash flows are addressed, rather than simply repeating the numerical data contained in the consolidated financial statements. Please refer to Instruction 4 to Item 303(a) of Regulation S-K.
TEM answered
No reply letter found.
Contractual Obligations and Commitments, page 118
SEC asked (14)
We note that the amount of total purchase obligations shown here is not consistent with the amounts presented on page F-25. Please revise to clarify the nature of the purchase obligations shown here and how the amounts presented were determined.Rest of the question
For example, to the extent that these represent obligations under data license agreements, it is unclear if amounts presented include estimates for additional payments contingent on the commercialization of data. Please also make any conforming changes, as necessary, on page F-25.
TEM answered
No reply letter found.
Critical Accounting Policies and Estimates · Revenue Recognition, page 119
SEC asked (15)
You disclose on page 166 that you only received payment on approximately 50% and 48% of your clinical oncology NGS tests during 2019 and 2020. It is unclear if you anticipated this level of reimbursement when you developed your estimates of variable consideration.Rest of the question
Please revise to discuss the significant judgements made in the application of your revenue accounting policies and the likelihood of materially different reported results if different assumptions or conditions were to prevail. Refer to Item 303(a) of Regulation S-K, SEC Interpretive Release No. 33-8350 and SEC Release No. 33-8040.
TEM answered
No reply letter found.
Critical Accounting Policies and Estimates · Revenue Recognition, page 119
SEC asked (16)
We note from your disclosures on pages 34 and 181 that all claims summitted to the Local MAC for NGS oncology tests performed for Medicare beneficiaries in your Chicago lab after March 25, 2021 have been denied. We further note that this type of testing represented 30% of your clinical testing volume as of June 30, 2021.Rest of the question
While you have begun the process of appealing these denials, it is unclear how you accounted for these claims and how your financial statements have been impacted. Please refer to SEC Release No. 33-8040, Item 303(a) of Regulation S-K and ASC 606-10-50-17. Please revise your disclosures here, in your MD&A and in your financial statement footnotes, as applicable, to: • Discuss any changes to your estimates of variable consideration. • Quantify the amount of unpaid receivable balances as of June 30, 3021 related to these denied claims. • Explain if and how you plan to pursue reimbursement from other sources if your denial appeals are not successful. • Quantify the amount of revenue recognized for NGS oncology tests performed for Medicare beneficiaries in your Chicago laboratory after March 25, 2021. • To the extent you continue to recognize revenue associated with NGS oncology tests performed for Medicare beneficiaries in your Chicago laboratory, tell us how you considered ASC 606-10-32-14.
TEM answered
No reply letter found.
Business · Ingestion and Generation of Data, page 129
SEC asked (17)
You disclose that you have approximately 200 direct data connections, many of which are bi-directional. Please revise to clarify if you are paying for the data you acquire and/or ingest. Please explain if there are any goods or services you provide to these entities in exchange for the data you receive.Rest of the question
Please also revise to address what happens to the data you have acquired if the providers who gave you access to data cease doing business with the Company. For example, it is unclear if you retain rights to sell and/or license the data acquired into perpetuity or only for a specific period of time.
TEM answered
No reply letter found.
Customer Facing Applications, page 132
SEC asked (18)
Please revise to more clearly explain the relationship between your customer facing applications (Hub and Lens) and your three product lines (Genomics, Data and Algos), including your primary Data products, Insights and Therapies.
TEM answered
No reply letter found.
Therapies, page 148
SEC asked (19)
Please revise to more fully describe the billing process for your Therapies product. For example, your disclosures on page 119 and F-15 indicate that the performance obligation is delivery of a notification of a matched patient for clinical trial or enrollment of a patient in a clinical trial. It is unclear how customers are notified that these performance obligations have been fulfilled.
TEM answered
No reply letter found.
Clinical Testing, page 166
SEC asked (20)
So that we may better understand your business, please revise to explain your responsibilities (if any) for finding a replacement patient or issuing a refund in the event that a patient you matched to a clinical trial decides not to proceed with (or unenrolls from) a clinical trial.Rest of the question
Please also clarify if the Company is obligated to identify a specific number of potential clinical trial candidates or enroll a certain number of patients into clinical trials over a given period. Consolidated Financial Statements 2. Summary of Significant Accounting Policies, page F-10
TEM answered
No reply letter found.
Clinical Testing, page 166
SEC asked (21)
You disclose on page 41 that some of your agreements with customers require you to cover the initial setup costs for Data products. If material, please revise to provide accounting policy disclosure for costs to obtain and/or fulfill contracts. Please refer to ASC 340-40.
TEM answered
No reply letter found.
Concentration of Credit Risk, page F-12
SEC asked (22)
Please revise to disclose revenue and accounts receivable customer concentrations as of and for the period ended June 30, 2021. For all periods presented, please also disclose concentrations in revenue due to COVID-19 testing. We note your disclosures on page 145 that you have shifted resources away from COVID-19 testing and do not expect the level of COVID-19 testing to be material to your business going forward.Rest of the question
Please refer to ASC 275-10-50-16 through 50-18.
TEM answered
No reply letter found.
Revenue Recognition, page F-14
SEC asked (23)
We note your disclosure on page 132 that you sometimes charge for access to Lens when a customer is interested in either a broader integration or some form of customization. Please tell us how you considered if access to Lens should be considered a separate performance obligation within your Data and other product offering. Please refer to ASC 606-10-25-14 through 25-22.
TEM answered
No reply letter found.
Revenue Recognition, page F-14
SEC asked (24)
You disclose on page 146 that for your Insights offering, customers pay either on a per file basis or through multi-year subscription agreements. You also indicate that you have signed contracts with a total remaining contract value of $172 million that you expect deliver to over the next several years.Rest of the question
Please revise your revenue recognition policy for data and other to describe the types of contracts available to customers, to disclose the average length of your multi-year subscription agreements, and to provide the disclosures required by ASC 606-10-50-13.
TEM answered
No reply letter found.
Revenue Recognition, page F-14
SEC asked (25)
On page 107, you disclose that through your Insights product, you license libraries of deidentified data and provide a suite of analytical services. Please tell us the nature of analytic services provided and explain how you determined those services did not represent a separate performance obligation.Rest of the question
Additionally, we note your disclosure on page 146 that data profiles regularly update with clinical outcome and response data over time. Please tell us and revise your filing as appropriate to explain your process for providing license updates to customers, the specific features and functionality that your updates and upgrades provide and how you account for those updates. Please specifically address how you considered if those updates represent a distinct performance obligation. Please refer to ASC 606-10-25-21.
TEM answered
No reply letter found.
Cost of Revenue, Genomics, page F-15
SEC asked (26)
You disclose on page F-15 that your cost of revenue, genomics includes third-party laboratory costs. So that we may better understand your business, please explain the nature of your contractual relationships with third-party laboratories, including the types of services performed by these labs.Rest of the question
Please tell us how you considered the involvement of third party labs in determining if you were acting as a principal or an agent in your contractual arrangements with customers. Please refer to ASC 606-10-55-36 through 5540.
TEM answered
No reply letter found.
Cost of Revenue, Genomics, page F-15
SEC asked (27)
You disclose on page 110 that, for the genomics product offering, costs associated with performing your tests are recorded at the time of report delivery. This seems inconsistent with disclosures on page F-15 indicating that costs are recorded as the tests are processed. Please revise as appropriate to correct this apparent discrepancy.Rest of the question
If costs are recorded at the time of report delivery, please explain to us the basis for this policy and describe to us the typical time delay between processing of tests and report delivery.
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (28)
Please revise to explain how you differentiate between expenses classified as Research and Development and those classified as Technology. To the extent that technology expenses do not qualify as research and development costs under either ASC 985-20-25 or 730-10-25, please tell us how your policy of excluding technology costs from cost of revenues and/or selling, general and administrative expenses complies withRest of the question
Rule 503(b)(2) of Regulation S-K. 5. Goodwill and Intangibles, page F-23
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (29)
Please revise to more fully explain the nature of your licensed data intangible asset, including how you acquired it, how it is used in your business and the relationship, if any, between this asset and your liabilities for accrued data licensing fees. 7. Stockholders' Equity, page F-26
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (30)
Please revise to address the conversion rights associated with Class B common stock as described on page 211. 9. Stock Based Compensation, page F-30
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (31)
Please provide us with a breakdown of the details of all stock-based compensation awards granted since January 1, 2021, including the fair value of the underlying stock used to value such awards. To the extent there were any significant fluctuations in the fair values, please describe for us the factors that contributed to such fluctuations, including any intervening events within the company or changes in yourRest of the question
valuation assumptions or methodology. 10. Convertible Promissory Notes, page F-32
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (32)
Please revise to explain how you account for principal reductions to your convertible promissory notes that are based upon the value of Google Cloud Platform services you use. Please also clarify the extent to which these notes require any minimum principal and/or interest payments prior to the maturity date.Rest of the question
We note disclosure on page F-23 that your current liabilities include $15.5 million of interest payable as of June 30, 2021 but it is unclear if these amounts pertain to your convertible promissory notes. 15. Subsequent Events, page F-38
TEM answered
No reply letter found.
Research and Development, page F-16
SEC asked (33)
Please revise to clarify if the negative impacts to your business as a result of COVID19 were also minimal for the six months ended June 30, 2021. Additionally, we note from your disclosure on page 22 that your COVID-19 testing agreement with CVS expired in July 2021.Rest of the question
Considering that this contract represented 24% of your revenues for the year ended December 31, 2020 and 42% of your revenues for the six months ended June 30, 2021, please revise to disclose the expiration of this agreement. Please refer to ASC 85510-50-2 and ASC 275-10-50-16 through 50-18.
TEM answered
No reply letter found.
Exhibits
SEC asked (34)
Please file the master agreement with Pathos AI, Inc. as a related party agreement. See Item 601(b)(10)(ii)(A) of Regulation S-K.
TEM answered
No reply letter found.
Exhibits
SEC asked (35)
Please file the convertible promissory note with Google LLC and the Google Cloud Platform Agreement as exhibits. Refer to Item 601(b)(4) of Regulation S-K. General
TEM answered
No reply letter found.
Exhibits
SEC asked (36)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
TEM answered
No reply letter found.
Data, page 7
SEC asked (1)
We note your response to prior comment 5. While we recognize the removal of references to the phrase "gross profit", the term "cohort lifetime value" could imply a fair market value associated with the cohort. Please consider an alternative that better reflects what the figure represents, such as "Cumulative revenue in excess of cost".
TEM answered
No reply letter found.
Data, page 7
SEC asked (2)
As a related matter, please address the following both here and elsewhere in the filing where this cohort analysis is presented: • Tell us why you have not provided a cohort analysis for the 6 months ended June 30, 2021.Rest of the question
• Revise your disclosures on page top of page 9 to clarify, if true, that sequencing revenue is a component of genomics net revenue, licensing revenue is a component of data and other revenue, and initial sequencing costs are a component of cost of revenues, genomics. • Quantify, to the extent possible, how much of your cost of revenues, data pertain to the licensing of the cohort data for the periods presented.
TEM answered
No reply letter found.
Management's Discussion and Analysis · Comparison of the Six Months Ended June 30, 2020 and 2021, page 113
SEC asked (3)
We note your response to prior comment 12. While we recognize the unique nature of each of the Company's contracts within the Data and other product category, please clarify for us if there are metrics or other measures used by management to evaluate the success of this revenue stream (for example, number of clinical trial matches, number of clinical trial enrollments and/or number of de-identified records deliveredRest of the question
per period). If so, please consider disclosing those metrics and any relevant trends so that investors have more context to understand fluctuations in your operating results between the periods presented.
TEM answered
No reply letter found.
Contractual Obligations and Commitments, page 119
SEC asked (4)
We note your response to prior comment 14. Please revise to present your discussion of material cash requirements from known contractual and other obligations as of the most recent fiscal period presented. Please refer to Item 303(b)(1) of Regulation S-K.
TEM answered
No reply letter found.
Consolidated Financial Statements · Summary of Significant Accounting Policies, page F-10
SEC asked (5)
We note your response to prior comment 21. We also note your disclosure on page 125 and elsewhere that you cover the actual direct costs associated with the technical integrations needed to create data connections with healthcare institutions. Please supplementally quantify the cost of these technical integrations.Rest of the question
If material, please revise to disclose your accounting policy for costs to obtain and/or fulfill contracts with customers. Please refer to ASC 340-40.
TEM answered
No reply letter found.
Revenue Recognition, page F-14
SEC asked (6)
We are considering your responses to comments 23 - 25. We may have further comments.
TEM answered
No reply letter found.
Consolidated Financial Statements · Revenue Recognition, page F-14
SEC asked
We note your responses to prior comments 23 through 25. So that we may better understand your accounting for refreshes, please supplementally address the following: • Explain in greater detail the nature of your performance obligations related to refreshes, including how they are defined and priced in your contracts with customers, the specific features and functionality refreshes provide, and the period of timeRest of the question
over which you are required to provide refreshes. • Tell us how you considered if these refreshes represent a stand-ready obligation to provide future products or services on a when-and-if-available basis. • Explain the consequences, if any, if you do not provide refreshes to your customers.
TEM answered
No reply letter found.
Management's Discussion and Analysis · Comparison of the Nine Months Ended September 30, 2020 and 2021, page 114
SEC asked (1)
In the discussion of changes in cost of revenues, you indicate that a portion of the increase was due to $11.3 million in service fees related to COVID-19 PCR testing arrangements. In the discussion of cost of revenues, genomics, you refer to an increase of $11.3 million in marketing expenses. If these increases refer to the same issue, please revise your MD&A to describe them consistently.
TEM answered
No reply letter found.
Management's Discussion and Analysis · Comparison of the Nine Months Ended September 30, 2020 and 2021, page 114
SEC asked (2)
You disclose on page F-33 that you have RSUs and PSUs subject to both a time based vesting condition and the occurrence of a liquidity event. If the successful completion of this IPO would be considered a liquidity event, please revise your MD&A to quantify the amount of stock based compensation that you expect to recognize in the next 12 months related to the vesting of any RSUs and PSUs that would meet bothRest of the question
conditions upon completion of an IPO.
TEM answered
No reply letter found.
Liquidity and Capital Resources · Operating Activities, page 119
SEC asked (3)
You disclose that one of the reasons for the net change in operating assets and liabilities for the nine months ended September 30, 2020 was a $4.2 million increase in accrued data licensing fees. You also indicate that $13.1 million of that increase is the result of extending the term of licensed data intangible.Rest of the question
It's unclear if this discussion of the $13.1 million increase contains a typo or if there are other offsetting factors affecting the increase in accrued data licensing fees. Please revise accordingly.
TEM answered
No reply letter found.
Dilution, page 102
SEC asked (1)
Please revise to more clearly disclose how you calculated historical net tangible book value per share as of December 31, 2021.
TEM answered
No reply letter found.
Management's Discussion and Analysis · Payor Coverage and Reimbursement, page 112
SEC asked (2)
We note your disclosure here and on pages 33-36. Your disclosure on page 112 references only payments received for clinical oncology NGS tests performed from January 1, 2020 through June 30, 2021. Please revise to address the following: • Clarify if you continued performing the NGS oncology tests from July 1, 2021 to December 31, 2021.Rest of the question
• If you continued performing these tests, please revise to also disclose payments received for those tests or explain why no payments have been received. • In your prior amendment, you disclosed that beginning in the second quarter of 2021, you estimated the reimbursement rate for tests performed as zero percent for these tests. You now disclose that you estimate a reimbursement rate that is "significantly reduced". Please revise to disclose how you accounted for this change and quantify the financial statement impact of this change on the periods presented. Please also refer to Item 303(b)(3) of Regulation S-K and revise disclosures on page 121 accordingly.
TEM answered
No reply letter found.
Comparison of the Years Ended December 31, 2020 and 2021 · Revenue, page 115
SEC asked (3)
Please revise your discussion of revenue and cost of revenue for both genomics and data and other so that the historical GAAP amounts are presented first, followed by any discussion of the results adjusted for the impact of COVID-19 PCR testing.Rest of the question
To the extent that your revenue or cost of revenue trends were different on a GAAP basis as compared to adjusted for the impact of COVID-19 PCR testing, please ensure that your MD&A addresses those differences in trends and describes the extent to which they are expected to continue. For example, it appears that in 2020, genomics revenues from COVID testing exceeded cost of revenues while that does not seem to be the case for other genomics revenues.
TEM answered
No reply letter found.
Data and Other, page 116
SEC asked (4)
Please revise your discussion of changes in data and other revenue to describe in greater detail the specific reasons for the $36 million (74%) increase from 2020 to 2021. For example, please provide greater context by quantifying the extent to which your business was impacted by new customers and quantifying the extent to which existing customers increased their adoption of products and services.
TEM answered
No reply letter found.
Quarterly Results of Operations, page 117
SEC asked (5)
Your disclosures on page 118 indicate that revenue and costs associated with COVID-19 testing begin to impact results in the second quarter of 2020. However, the table on page 117 only quantifies the impacts of COVID-19 testing beginning with the third quarter of 2020. Please revise accordingly.
TEM answered
No reply letter found.
Quarterly Results of Operations, page 117
SEC asked (6)
Please revise your discussion of quarterly costs and operating expense trends on page 118 to explain what caused the significant decline in genomics cost of revenue associated with COVID-19 testing relative to genomics revenue from COVID-19 testing during the last three quarters of fiscal 2021 compared to the previous three quarters. Consolidated Financial Statements 2. Summary of Significant Accounting Policies
TEM answered
No reply letter found.
Revenue Recognition, page F-13
SEC asked (7)
We note your discussion of the November 2021 Master Services Agreement with AstraZeneca on pages 110 and F-15. Please tell us if AstraZeneca will be required to pay any penalties to you if they do not meet the $200 minimum purchase commitment. Please also tell us how you considered if this agreement provides the customer with a material right. Please refer to ASC 606-10-55-41 through 55-45.
TEM answered
No reply letter found.
Draft Registration Statement on Form S-1 submitted April 27, 2022 · Dilution, page 102
SEC asked (1)
We note in your response to prior comment 1 that historical net tangible book value "represents the amount of our total tangible assets less our total liabilities and the carrying value of our redeemable convertible preferred stock." Please provide us your calculation, referencing the amounts reported on your balance sheet, to support a historical net tangible book value of $33.7 million as of December 31, 2021.
TEM answered
No reply letter found.
Management's Discussion and Analysis of Financial Condition and Results of Operations, page · 106
SEC asked (2)
You state that through December 2021, the 12-month retention rate for oncologists ordering more than 5 tests were 92%. Disclose the number of oncologists used to measure the retention rate. Discuss how the retention rate was measured and the time period. To the extent material, disclose the total number of customers for all periods presented in each of your three product lines.
TEM answered
No reply letter found.
Comparison of the Years Ended December 31, 2020 and 2021 · Revenue, page 115
SEC asked (3)
We note your response to prior comment 3. Please revise to also address the reasons for changes in cost of revenues, genomics. For example, it is unclear what caused the $15.6 million increase in material and service costs and the inventory write-downs of $1.8 million.Rest of the question
Similarly, it is unclear why you experienced a $10.8 million decrease in cost of revenues, genomics associated with COVID-19 PCR testing despite a $5 million increase in PCR testing revenues over the same period.
TEM answered
No reply letter found.
Data and Other, page 116
SEC asked (4)
We note your response to prior comment 4. Please revise to provide greater context to investors by quantifying the increase in the number of new customers that adopted your data and other products during 2021 as compared to 2020. Consolidated Financial Statements 9. Stock-Based Compensation, page F-29
TEM answered
No reply letter found.
Data and Other, page 116
SEC asked (5)
To the extent there have been any recent developments, please provide us with an update to your October 28, 2021 response to comment 31 regarding stock based compensation awards.
TEM answered
No reply letter found.
Consolidated Financial Statements
SEC asked
Stock-Based Compensation, page F-29 1. We note your response to prior comment 5. Please provide us with a breakdown of the details of all stock-based compensation awards granted since August 1, 2021, including the fair value of the underlying stock used to value such awards.Rest of the question
To the extent there were any significant fluctuations in the fair values, please describe for us the factors that contributed to such fluctuations, including any intervening events within the company or changes in your valuation assumptions or methodology.
TEM answered
No reply letter found.
Consolidated Financial Statements
SEC asked
Stock-Based Compensation, page F-34 1. We note your response to comment 1 from our letter dated October 27, 2022. Please revise to your disclosures here, on pages 126-127, and elsewhere as appropriate, to explain the change in your valuation methodology for stock-based compensation awards during the periods presented.
TEM answered
No reply letter found.
Prospectus Summary, page 1
SEC asked (1)
You state that you have established data partnerships with approximately 90% of the largest public pharmaceutical companies based on 2022 revenue. Please discuss the material terms of your data partnerships, including the financial terms of any agreements. Management, page 195
TEM answered
No reply letter found.
Prospectus Summary, page 1
SEC asked (2)
We note that your COO is now also the interim CEO for Pathos AI, Inc. We also note your disclosure that you are highly dependent on members of your senior management team. Please revise your risk factor on page 79 to disclose the percentage of time that your COO devotes to the business of the company given his other responsibilities as the interim CEO of Pathos.Rest of the question
Additionally, please revise your discussion of your agreements with Pathos on page 216 to include Mr. Fukushima's new role at Pathos.
TEM answered
No reply letter found.
Financial Statements · Note 16. Subsequent Events, page F-43
SEC asked (3)
We note that the amended Credit Agreement with Ares on April 25, 2023 included an increase in the interest rate. Please expand the disclosure to include the interest rate in the amended agreement. Please expand the discussion of the Term Loan Facility in MD&A accordingly.
TEM answered
No reply letter found.